Defining the cellular and molecular mechanisms driving neointimal lesion growth in pulmonary hypertension

定义驱动肺动脉高压新内膜病变生长的细胞和分子机制

• 批准号: 10594934
• 负责人: Maya Elise Kumar
• 金额: $ 66.83万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-20 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10594934
• 关键词: Ablation; Address; Adult; Affect; Arteries; Automobile Driving; Bioinformatics; Biological Models; Biology; Cell division; Cells; Cessation of life; Child; Consensus; Data; Data Set; Development; Disease; Drug usage; Endothelial Cells; Endothelium; Gene Expression; Gene Expression Profile; Generations; Genetic; Genetic Transcription; Genomics; Growth; Growth and Development function; Human; In Situ; Knowledge; Lesion; Location; Lung; Lung diseases; Modeling; Molecular; Molecular Profiling; Morbidity - disease rate; Mus; NOTCH3 gene; Pathology; Pathway interactions; Patients; Persons; Pharmaceutical Preparations; Positioning Attribute; Process; Proliferating; Pulmonary Hypertension; Pulmonary Vascular Resistance; Pulmonary artery structure; Rattus; Rodent Model; Role; Sampling; Signal Pathway; Signal Transduction; Supportive care; Technology; Testing; Tissues; Transgenic Mice; Vascular remodeling; Vascular resistance; Vasodilator Agents; WNT Signaling Pathway; beta catenin; bioinformatics tool; candidate identification; cell type; cellular targeting; drug isolation; drug testing; effective therapy; experimental study; genetic testing; hemodynamics; improved; in vivo; inhibitor; mortality; mouse genetics; neointima formation; notch protein; novel; prevent; pulmonary arterial hypertension; right ventricular failure; single cell analysis; single-cell RNA sequencing

Project Summary/Abstract Pulmonary hypertension (PH) is a fatal disease of the pulmonary arteries with few supportive therapies and no cure. In PH, occlusive `neointimal lesions' grow within small pulmonary arteries and narrow vessel lumens, increasing pulmonary vascular resistance, ultimately resulting in right heart failure and death. Available PH therapies are vasodilators that do not target neointimal growth and neither prevent progression nor reverse disease. Understanding the biology of neointimal lesion growth – which cells are responsible for lesion expansion, and the pathways that control their proliferation – is key to the development of more effective therapies for pulmonary hypertension. In preliminary studies we find that proliferating neointima cells are adjacent to artery endothelial cells and have distinct gene expression that distinguishes them from cells located away from the endothelium. We hypothesize that a molecularly defined subset of neointimal cells located adjacent to the endothelium is the proliferating fraction that expands neointimal lesions, and that signals from the endothelium regulate lesion growth. Specific Aims: (1) Using proliferation tracking, genetic lineage tracing and ablation, identify and molecularly characterize the subset of neointimal cells whose proliferation is responsible for lesion growth. (2) Through bioinformatic analysis of single cell transcription in neointima and artery endothelial cells from mouse and human, identify candidate signals driving neointimal proliferation in PH and the core disease mechanisms shared between mouse and human. (3) Test the ability of a key candidate driver of neointimal proliferation for a role in lesion growth in multiple PH models. Here, by utilizing cutting edge technologies, genetics, and single cell approaches across multiple model systems, these experiments will provide a granular understanding of the cells and signals driving neointimal lesion expansion, adding substantially to the current knowledge surrounding the pathology of vascular remodeling in PH, findings we hope will ultimately lead to neointima-blocking treatment options.

项目总结/文摘